Drug Topics - November 5, 2007 - (Page 35)

35 TEST QUESTIONS 4. Once weight loss is stabilized, HDL-C levels are 11. In the Copenhagen City Heart Study, patients improved by how much per kilogram of weight loss? a. 0.35 mg/dl b. 0.5 mg/dl c. 0.75 mg/dl d. 1 mg/dl 5. Niacin is contraindicated in patients with: a. Diabetes b. Gout c. Peptic ulcer disease d. Renal dysfunction 6. Which of the following is not a type of therapy had a reduced risk for heart disease if they drank: a. Beer b. Nothing c. Spirits d. Wine 12. A patient receives a lipid panel that indicates she needs to raise her HDL-C by about 10% to achieve an HDL-C level >50 mg/dl. Barring any contraindications, which of the following may potentially raise her HDL-C level? a. Aerobic exercise for at least 150 minutes each week b. Gemfibrozil 600 mg p.o. b.i.d. c. Niacin 500 mg daily, titrating up to 2,000 mg/day d. All of the above 13. What estimated percentage of men have HDL-C being studied for the treatment of low HDL-C levels? a. ApoA-I antagonists b. CETP inhibitors c. Novel formulations of nicotinic acid d. PPAR agonists 7. Which of the following describes the role of the levels <35 mg/dl? a. 1% to 2% b. 3% to 6% c. 16% to 18% d. 20% to 25% 14. A patient with diabetes receiving niacin for dys- pharmacist in helping patients with low HDL-C levels? a. Counseling on the methods to reduce flushing associated with niacin b. Discouraging any use of OTC products such as soy or niacin due to a lack of efficacy c. Encouraging patients to follow up with their healthcare providers for lab assessment whenever they feel their cholesterol is too low. d. Making recommendations for therapy without asking questions for fear of appearing too inquisitive. 8. A patient asks the pharmacist whether niacin lipidemia should have which of the following parameters monitored? a. Blood glucose levels b. Lipid panel c. Liver function tests d. All of the above 15. ER niacin/laropiprant is a novel nicotinic acid therapy is appropriate for him. He has a history of diabetes and hypertension. Which of the following questions would not be appropriate to ask this patient before making any recommendations regarding niacin? a. Do you have any problems with your liver? b. How have your blood pressures been ranging? c. How have your blood sugar readings been ranging? formulation that is proposed, as compared with current formulations, to have a reduction in which of the following side effects? a. Flushing b. Hepatotoxicity c. Hyperglycemia d. Hyperuricemia 16. The HATS trial showed a 90% reduction in car- diovascular outcomes for the treatment arm that received: a. Atorvastatin b. Gemfibrozil c. Fenofibrate and pravastatin d. Niacin and simvastatin 17. It is theorized that the inhibition of the choles- d. Were you advised to seek a product with niacin for your cholesterol? 9. Clinical trials have found that niacin can raise HDL-C levels by: a. 5% to 15% b. 10% to 26% c. 20% to 50% d. 35% to 50% 10. Other than niacin, the next class of prescription teryl ester transfer protein results in the increase of which HDL subtype? a. CE-poor HDL b. Mature-alpha HDL c. Pre-beta HDL d. TG-rich HDL 18. The study involving apoA-I Milano/phospho- medications that can potentially raise HDL-C levels the greatest are: a. Bile acid sequestrants b. Cholesterol absorption inhibitors c. Fibric acid derivatives d. Statins lipid complex used which of the following as an outcome measure? a. Change in the TC-to-HDL ratio b. Increase in HDL subtypes c. Percent of coronary atheroma volume d. Risk of myocardial infarction

Table of Contents Feed for the Digital Edition of Drug Topics - November 5, 2007

Drug Topics - November 5, 2007 Contents Latebreakers Latebreakers in Depth Letters Rx Care Community Practice 150 Years of American Pharmacy Hospital Practice Pharmacists at Risk Government and Law High-Density Lipoprotein New Products Advertisers Index Classified Viewpoint

Drug Topics - November 5, 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.